[go: up one dir, main page]

MX2021010033A - Composiciones microencapsuladas de cannabinoides. - Google Patents

Composiciones microencapsuladas de cannabinoides.

Info

Publication number
MX2021010033A
MX2021010033A MX2021010033A MX2021010033A MX2021010033A MX 2021010033 A MX2021010033 A MX 2021010033A MX 2021010033 A MX2021010033 A MX 2021010033A MX 2021010033 A MX2021010033 A MX 2021010033A MX 2021010033 A MX2021010033 A MX 2021010033A
Authority
MX
Mexico
Prior art keywords
cannabinoids
compositions
microencapsulated compositions
microencapsulated
encapsulated
Prior art date
Application number
MX2021010033A
Other languages
English (en)
Inventor
William Kleidon
Justin Kirkland
Original Assignee
Ojai Energetics Pbc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ojai Energetics Pbc filed Critical Ojai Energetics Pbc
Publication of MX2021010033A publication Critical patent/MX2021010033A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00—Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/001—Spread compositions
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
    • A23G9/00—Frozen sweets, e.g. ice confectionery, ice-cream; Mixtures therefor
    • A23G9/52—Liquid products; Solid products in the form of powders, flakes or granules for making liquid products ; Finished or semi-finished solid products, frozen granules
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/52—Adding ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/206—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin
    • A23L29/256—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of vegetable origin from seaweeds, e.g. alginates, agar or carrageenan
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/04—Dispersions; Emulsions
    • A61K8/06—Emulsions
    • A61K8/068—Microemulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/73—Polysaccharides
    • A61K8/733—Alginic acid; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Nutrition Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Birds (AREA)
  • Botany (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)

Abstract

La presente invención se refiere a composiciones de cannabinoides. Estas composiciones se pueden encapsular (por ejemplo, microencapsular). En particular, estas composiciones se pueden administrar a un sujeto, tal como a través de consumo oral o tratamiento tópico.
MX2021010033A 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides. MX2021010033A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462091445P 2014-12-12 2014-12-12
US201562128761P 2015-03-05 2015-03-05
PCT/US2015/065268 WO2016094810A2 (en) 2014-12-12 2015-12-11 Microencapsulated cannabinoid compositions

Publications (1)

Publication Number Publication Date
MX2021010033A true MX2021010033A (es) 2022-08-25

Family

ID=56108379

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2021010033A MX2021010033A (es) 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides.
MX2017007550A MX2017007550A (es) 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017007550A MX2017007550A (es) 2014-12-12 2015-12-11 Composiciones microencapsuladas de cannabinoides.

Country Status (12)

Country Link
US (2) US10080736B2 (es)
EP (1) EP3229789A4 (es)
JP (3) JP2018505912A (es)
CN (2) CN107205981A (es)
AU (2) AU2015360349B2 (es)
BR (1) BR112017012434A2 (es)
CA (1) CA2970651C (es)
EA (1) EA201791299A1 (es)
HK (1) HK1244710A1 (es)
IL (2) IL252881B (es)
MX (2) MX2021010033A (es)
WO (1) WO2016094810A2 (es)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10350165B2 (en) 2014-12-12 2019-07-16 Ojai Energetics Pbc Methods and systems for forming stable droplets
CA3176674A1 (en) 2015-05-18 2016-11-24 5071, Inc. Homogenous cannabis compositions and methods of making the same
US10369178B2 (en) * 2016-03-06 2019-08-06 Resurgent Pharmaceuticals, Inc. Tobacco products with cannabinoid additives and methods for reducing the harm associated with tobacco use
JP7053054B2 (ja) 2016-04-15 2022-04-12 エスアールイー ウェルネス，インク． 大麻注入甘味料及び他の組成物
US20220087972A9 (en) 2016-04-15 2022-03-24 Sre Wellness, Inc. Cannabinoid Compositions
US20180206518A1 (en) 2016-04-15 2018-07-26 Ronald Silver Method of making cannabis oil hydrophilic using emulsifiers and related cannabinoid compositions
AU2017286659A1 (en) * 2016-06-15 2019-01-17 Ojai Energetics Pbc Methods and compositions for reducing oxidative stress
JP2019518760A (ja) * 2016-06-15 2019-07-04 オーハイ エナジェティクス ピービーシー 幹細胞療法を増強するための方法および組成物
KR20190035791A (ko) 2016-08-03 2019-04-03 젤다 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
KR102447510B1 (ko) 2016-08-03 2022-09-27 젤리라 테라퓨틱스 오퍼레이션즈 피티와이 엘티디 카나비스 조성물
EP3538122B1 (en) * 2016-11-14 2025-03-26 Farm To Farma, Inc. Cannabinoid formulations and method of making the same
US10239808B1 (en) 2016-12-07 2019-03-26 Canopy Holdings, LLC Cannabis extracts
EP3558281A4 (en) * 2016-12-15 2020-07-08 Sharon Anavi-Goffer TREATMENT OF MENTAL DISORDERS, MOVEMENT AND BEHAVIOR
MX2019007496A (es) * 2016-12-20 2019-10-30 Tilray Inc Composiciones cannabinoides novedosas y metodos para tratar la epilepsia infantil.
KR20190124785A (ko) * 2017-03-18 2019-11-05 스티븐 엠. 맥개러 칸나비디올산을 포함하는 반려동물 식품
EP3600285A4 (en) * 2017-03-27 2021-01-13 Patagonia Pharmaceuticals, LLC TOPICAL COMPOSITIONS AND METHODS OF TREATMENT
US11096349B2 (en) * 2017-08-02 2021-08-24 Insectergy, Llc Cannabis farming systems and methods
CN110913839A (zh) * 2017-05-22 2020-03-24 Gbs全球生物制药公司 靶向trpv1的含月桂烯和大麻素的组合物
BR112019024911A2 (pt) * 2017-05-26 2020-09-01 Altum Pharmaceuticals Inc. entrega de canabinoide biphasix
CA3067436A1 (en) * 2017-06-16 2018-12-20 Frantisek Bednarik A composite mixture comprising cannabis sativa
AU2018100837B4 (en) 2017-06-19 2019-02-21 Zelira Therapeutics Operations Pty Ltd Sleep Disorder Compositions and Treatments Thereof
MX2019015673A (es) * 2017-06-30 2020-02-26 Creso Pharma Switzerland Gmbh Composicion de granulos veterinarios que contiene extracto de ca?amo.
WO2019014631A1 (en) * 2017-07-14 2019-01-17 5071, Inc. CANNABINOID COMPOSITIONS AND PREPARATION METHODS THEREFOR
CO2017007962A1 (es) * 2017-08-04 2018-04-19 Alsec Alimentos Secos S A S Nanoparticulas oleosas de cannabis microencapsuladas en polvo
IL272709B2 (en) 2017-09-08 2024-09-01 Scicann Therapeutics Inc Compositions comprising a cannabinoid and spilanthol
CN107903655A (zh) * 2017-10-18 2018-04-13 湖北科技学院 一种从桂花果皮中提取黑色素的方法及其应用
CA3080434A1 (en) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations
US20200330378A1 (en) * 2018-01-03 2020-10-22 Icdpharma Ltd. Taste-enhanced cannabinoid submicron emulsion syrup compositions
US20210052478A1 (en) * 2018-01-05 2021-02-25 Altus Labs, Llc Personal care compositions
US12035732B1 (en) * 2018-01-29 2024-07-16 Nouv Eau Inc. Composition of matter and method of use for wine health mixtures
US11202771B2 (en) 2018-01-31 2021-12-21 Treehouse Biotech, Inc. Hemp powder
CA3093414C (en) * 2018-03-14 2022-12-13 Poviva Tea, Llc Transdermal and/or dermal delivery of lipophilic active agents
JP2021521277A (ja) 2018-04-09 2021-08-26 エレヴェット・サイエンシズ 動物における疼痛の処置のためのアサ抽出物
GB201806953D0 (en) * 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
AU2019285379A1 (en) * 2018-06-15 2021-02-04 CannPal Animal Therapeutics Limited Cannabinoid composition and methods of treatment using the same
GB2576636B (en) * 2018-08-06 2022-03-30 Ubeauty Global A tanning composition
CN109045045B (zh) * 2018-08-14 2020-10-09 淮南师范学院 一种治疗心脑血管疾病的中药活性成分组合物
US11517685B2 (en) 2019-01-18 2022-12-06 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
CA3110469A1 (en) 2018-08-22 2020-02-27 Respira Technologies, Inc. Electronic device for producing an aerosol for inhalation by a person
US11690963B2 (en) 2018-08-22 2023-07-04 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
WO2020044118A1 (en) * 2018-08-27 2020-03-05 Emerald Health Therapeutics Canada Inc. Improved cannabinoid bioavailability
US10966924B2 (en) 2018-09-04 2021-04-06 Babak Ghalili Veterinary cannabinoid, menthol and anesthetic compositions and methods
US11185526B2 (en) 2018-09-04 2021-11-30 Babak Ghalili Cannabinoid, menthol and caffeine dissolvable film compositions, devices and methods
US10751299B2 (en) 2018-09-04 2020-08-25 Babak Ghalili Cannabinoid and menthol compositions and methods
US11147775B2 (en) 2018-09-04 2021-10-19 Babak Ghalili Cannabinoid and menthol gel compositions, patches and methods
IL261774B (en) * 2018-09-13 2020-04-30 Unv Medicine Ltd Compositions for treating dermatological conditions
MX2021003832A (es) * 2018-10-04 2021-09-08 India Globalization Capital Inc Metodo y composicion para aliviar la fatiga y restaurar la energia.
EP3863453A4 (en) * 2018-10-18 2022-11-23 Qnovia, Inc. Electronic device for producing an aerosol for inhalation by a person
CN111183989A (zh) * 2018-11-14 2020-05-22 北京中以新农高科商务咨询有限公司 包含胶囊化挥发性精油和溶解在其中的聚合物的农用制剂
GB2579179A (en) * 2018-11-21 2020-06-17 Gw Res Ltd Cannabidiol-type cannabinoid compound
US11458092B2 (en) 2018-12-14 2022-10-04 NuVessl, Inc. Composition with enhanced passenger molecule loading
GB2615034A (en) * 2018-12-18 2023-07-26 Ojai Energetics Pbc Cannabinoid compositions for virtual and augmented reality experiences
US20220054380A1 (en) * 2018-12-25 2022-02-24 Epm (Ip), Inc. Cannabidioloic acid esters for cosmetic or edible compositions
AU2019412825A1 (en) * 2018-12-27 2021-08-12 Buzzelet Development And Technologies Ltd. Herbal preparation-enriched cannabinoid composition and method of treatment
WO2020136627A1 (en) * 2018-12-29 2020-07-02 Buzzelet Development And Technologies Ltd. Isolated or synthetic cannabinoid compositions with selected terpene blend and methods of use thereof
US20220079880A1 (en) * 2019-01-17 2022-03-17 Thomas Piccariello Solid micellar compositions of cannabinoid acids
AU2020215164A1 (en) * 2019-01-29 2021-09-16 Buzzelet Development And Technologies Ltd. Terpene-enriched cannabinoid composition and method of treatment for treating conditions and/or symptoms associated with autism spectrum disorder
EP3931330A4 (en) 2019-02-25 2023-03-15 Ginkgo Bioworks, Inc. BIOSYNTHESIS OF CANNABINOIDS AND CANNABINOID PRECURSORS
EP3941458A4 (en) * 2019-03-21 2022-05-25 Alvit LCS Pharma Ltd. FIXED-DOSE COMBINATION OF CANNABINOIDS AND MEDICAL MUSHROOMS FOR THE PREVENTION AND TREATMENT OF CANCER, INFLAMMATORY OR IMMUNE-MEDIATED INFLAMMATORY DISEASES
IL294125B2 (en) * 2019-05-06 2025-03-01 Transp Authority Inc Systems and methods for producing cannabis edibles and edible products resulting therefrom
EP3968970A4 (en) * 2019-05-16 2023-01-25 Buzzelet Development And Technologies Ltd LOCAL ANESTHETIC COMPRISING A TRP CHANNEL MODULATOR
CN110025595A (zh) * 2019-05-27 2019-07-19 西宝生物科技（上海）股份有限公司 一种高稳定可水溶性工业大麻cbd微囊的制备方法
WO2020264052A1 (en) * 2019-06-24 2020-12-30 Hempvana, Llc Compositions comprising cannabis sativa oil and uses thereof
US11622956B1 (en) 2019-06-26 2023-04-11 RCR BioPharma Compound and method for treating diseases and disorders
US10588871B1 (en) 2019-06-28 2020-03-17 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
AU2019454044A1 (en) * 2019-06-28 2022-01-20 Nexzol Pharma, Inc. Transdermal formulation for the treatment of pain and/or inflammation
CA3145830A1 (en) * 2019-07-02 2021-01-07 Ellevet Sciences Hemp extract for treatment of pain, cancer and epilepsy in animals
US20210023023A1 (en) * 2019-07-25 2021-01-28 Vasayo, Llc Liposomal nutraceutical compositions and methods of making the same
US20210023005A1 (en) 2019-07-26 2021-01-28 Landsteiner Scientific S.A. De C.V. Cannabinoid-containing compositions in the form of spheres or sphere-like particles, methods for their preparation, and therapeutic applications
EP4009800A4 (en) * 2019-08-06 2023-08-16 Nuka Enterprises CONSUMABLE COMPOSITIONS AND THEIR PRODUCTION METHODS
WO2021041404A1 (en) * 2019-08-26 2021-03-04 Filipetto Gianna Marie Method and apparatus for the infusion of cannabinoids into a shelf-stable food composition
US20210169820A1 (en) 2019-09-12 2021-06-10 Nulixir Inc. Controlled release concentrate and suspensions including the same
US11542243B1 (en) 2019-09-26 2023-01-03 FusionFarms, LLC Method of converting delta9-THC to delta10-THC and the purification of the delta10-THC by crystallization
US20210113783A1 (en) 2019-10-20 2021-04-22 Respira Technologies, Inc. Electronic devices and liquids for aerosolizing and inhaling therewith
IL294203A (en) * 2019-12-28 2022-08-01 Buzzelet Development And Technologies Ltd Liquid compositions comprising terpenes and cannabinoids
WO2021178465A1 (en) * 2020-03-02 2021-09-10 Clear Lake Research, Llc Buccal and enteric delivery of fatty acids with oral hygiene practices
US20220071946A1 (en) * 2020-03-03 2022-03-10 Alte Verde Llc Cannabis Treatment of Insomnia, Pain, and Skin Conditions
EP4125834A4 (en) * 2020-03-30 2024-05-08 Ojai Energetics PBC SYSTEMS, METHODS AND COMPOSITIONS FOR INFECTIONS
EP4135687A4 (en) * 2020-04-17 2024-04-17 University of Connecticut POLYCANNABINOIDS, COMPOUNDS, COMPOSITIONS AND METHODS OF USE
WO2021216640A1 (en) * 2020-04-21 2021-10-28 Coolhouse Sourcing Llc Composition, article and method for affecting a mammal
AU2021376539A1 (en) * 2020-11-06 2023-06-15 Zelira Therapeutics Operations Pty Ltd Cannabinoid encapsulation technology
CN112472661A (zh) * 2020-12-11 2021-03-12 云南苏旺润生物医药有限公司 一种大麻二酚按摩油组合物及其制备方法和应用
US20220218649A1 (en) * 2021-01-07 2022-07-14 Mai Nguyen Composition for treating opioid withdrawal and method of manufacture
KR102278512B1 (ko) 2021-01-19 2021-07-20 정진욱 광화학 반응시켜 카나비디올 및 풀빅산을 함유하며, 상기 카나비디올 및 풀빅산 성분이 식용 곤충, 파충류, 연체류, 및 가축류로의 천이 가능한 사료 조성물 및 이의 제조방법
US20220266206A1 (en) * 2021-02-19 2022-08-25 Gaia Botanicals Llc Dba Bluebird Botanicals Formulation and process for manufacturing a heat stable oil-in-water emulsion for cannabis beverages in plastic bottles
IT202100006893A1 (it) * 2021-03-22 2022-09-22 Kolinpharma S P A Una formulazione in forma di microgranuli comprendente un estratto o molecola di origine vegetale avente effetti gastrolesivi o instabilità a ph acido, e una matrice gastroresistente
US11844361B2 (en) 2021-04-08 2023-12-19 Wiparo Biomed Limited Stem cell boosting chocolate composition
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
CN113332278A (zh) * 2021-06-03 2021-09-03 威海华新药业集团有限公司 一种靛红和二氢大麻酚复合物及其医疗用途
WO2022269616A1 (en) * 2021-06-24 2022-12-29 Ramot At Tel-Aviv University Ltd. Combination compositions for the treatment of pathogen infections and associated complications
US20230000936A1 (en) * 2021-06-30 2023-01-05 Demetrix, Inc. Alleviation of itching sensations using cannabinoid compounds
EP4134073A1 (en) 2021-08-11 2023-02-15 HM HerbaMedica GmbH Pharmaceutical compositions comprising dendritic nanocarriers and cannabis active agents
CA3130284A1 (en) * 2021-09-09 2023-03-09 Faezeh Dousty Cannabinoid-humic substances composition and method of making the same
EP4499109A1 (en) * 2022-03-25 2025-02-05 Ojai Energetics PBC Psychedelic compositions and methods for forming the same
TW202404490A (zh) 2022-04-22 2024-02-01 美商奎諾維亞公司 用於霧化和吸入液體的電子設備
WO2023245107A1 (en) * 2022-06-15 2023-12-21 Phyto Tech Corp. Microencapsulation of cannabidiol or its mixture with nicotine for oral and topical administration
CN115068441B (zh) * 2022-06-30 2023-04-14 东北农业大学 一种水溶性大麻二酚微胶囊及其制备方法
CN115364050B (zh) * 2022-08-02 2023-07-18 无锡诺平医药科技有限公司 H2cbd乳液、制备方法及其药物应用
WO2024154119A1 (en) * 2023-01-19 2024-07-25 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Enriched pelargonium graveolens extracts for the treatment of traumatic brain injuries

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3456049A (en) 1965-05-25 1969-07-15 Ciba Geigy Corp Gradual-release tablet
JPS5948414A (ja) * 1982-09-10 1984-03-19 Asahi Denka Kogyo Kk ビタミンｅの水溶性製剤
JPS6051104A (ja) * 1983-08-30 1985-03-22 Ajinomoto Co Inc ビタミンｅ含有水性液剤
JPS6398369A (ja) * 1986-10-14 1988-04-28 Maruzen Kasei Kk 飲料用クラウデイ−
US4888194A (en) * 1986-12-10 1989-12-19 Borden, Inc. Shelf-stable aseptic dairy product
US5674522A (en) * 1993-10-07 1997-10-07 Mcneil-Ppc, Inc. Beverage concentrate for drug delivery
US5885594A (en) * 1997-03-27 1999-03-23 The Procter & Gamble Company Oral compositions having enhanced mouth-feel
WO2002070506A2 (en) 2001-03-07 2002-09-12 Websar Innovations Inc. Conversion of cbd to δ8-thc and δ9-thc
DE10258867A1 (de) * 2002-12-17 2004-07-08 Bayer Cropscience Gmbh Mikroemulsionskonzentrate
ES2235642B2 (es) * 2003-12-18 2006-03-01 Gat Formulation Gmbh Proceso de multi-microencapsulacion continuo para la mejora de la estabilidad y almacenamiento de ingredientes biologicamente activos.
GB0409104D0 (en) * 2004-04-23 2004-05-26 Norgine Europe Bv Compressed pharmaceutical compositions
AU2005265031A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
GB0504950D0 (en) * 2005-03-10 2005-04-20 Novartis Ag Organic compositions
US8017152B2 (en) * 2005-05-27 2011-09-13 Stratosphere Pharma Ab Cores and microcapsules suitable for parenteral administration as well as process for their manufacture
WO2006138227A1 (en) 2005-06-16 2006-12-28 Forest Laboratories, Inc. Modified and immediate release memantine bead formulation
US20080242741A1 (en) * 2007-03-30 2008-10-02 Wayne Jeffrey Perry Intranasal drug delivery system
US20090110674A1 (en) * 2007-10-24 2009-04-30 Loizou Nicos C Health supplement
CA2780295A1 (en) * 2009-10-09 2011-04-14 Atheronova Operations, Inc. Compositions and methods for treating obesity
CA2792330C (en) * 2010-03-23 2017-01-03 Virun, Inc Nanoemulsion including a peg-derivative of vitamin e and a sucrose fatty acid ester
US20120043242A1 (en) 2010-08-19 2012-02-23 Andrew David Hospodor Medicinal cannabis fatty foodstuff
US20120231083A1 (en) * 2010-11-18 2012-09-13 The Board Of Trustees Of The University Of Illinois Sustained release cannabinoid medicaments
CA2820751A1 (en) * 2010-12-10 2012-06-14 The Governors Of The University Of Alberta Barley protein microcapsules
US8808734B2 (en) 2011-07-11 2014-08-19 Full Spectrum Laboratories Limited Cannabinoid formulations
GB2495118B (en) * 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
ES2739194T3 (es) * 2012-01-19 2020-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulación y método para aumentar la biodisponibilidad oral de fármacos
US20150313868A1 (en) * 2012-12-18 2015-11-05 Kotzker Consulting Llc Use of cannabinoids and terpenes for treatment of organophosphate and carbamate toxicity
JP6581509B2 (ja) 2013-02-28 2019-09-25 ティーウィノット テクノロジーズ リミテッド 化合物を合成する化学工学プロセス及び装置
AU2014347807A1 (en) * 2013-10-31 2016-05-26 Full Spectrum Laboratories, Ltd. Terpene and cannabinoid formulations
WO2016053809A1 (en) 2014-09-29 2016-04-07 Barrie Tan Non-synthetic emulsion-based lipid formulations and methods of use

Also Published As

Publication number Publication date
AU2015360349B2 (en) 2020-10-08
AU2021200019A1 (en) 2021-03-18
IL292818A (en) 2022-07-01
CA2970651A1 (en) 2016-06-16
EA201791299A1 (ru) 2017-12-29
EP3229789A2 (en) 2017-10-18
US20170172977A1 (en) 2017-06-22
HK1244710A1 (zh) 2018-08-17
AU2015360349A1 (en) 2017-07-06
JP2018505912A (ja) 2018-03-01
AU2021200019B2 (en) 2022-06-02
IL252881B (en) 2022-06-01
US20180344686A1 (en) 2018-12-06
MX2017007550A (es) 2018-05-04
JP2022023230A (ja) 2022-02-07
IL252881A0 (en) 2017-08-31
WO2016094810A2 (en) 2016-06-16
CA2970651C (en) 2020-09-29
CN107205981A (zh) 2017-09-26
WO2016094810A3 (en) 2016-10-13
BR112017012434A2 (pt) 2018-02-20
US10080736B2 (en) 2018-09-25
CN118436616A (zh) 2024-08-06
JP2024015115A (ja) 2024-02-01
NZ732700A (en) 2024-07-05
EP3229789A4 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
MX2021010033A (es) Composiciones microencapsuladas de cannabinoides.
LTPA2021003I1 (lt) Kompozicijos, naudojamos gydyti sutrikimams, susijusiems su KIT
MY165124A (en) Semifluorinated alkane compositions
BR112016002391A2 (pt) composições tópicas e métodos de uso das mesmas
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
EA201691259A1 (ru) РЕГУЛЯТОРЫ Nrf2
EA201692301A1 (ru) Производные бороновой кислоты и их терапевтическое применение
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
EA201790273A1 (ru) Флагеллиновые композиции и их применение
JOP20140114B1 (ar) مركبات حلقية غير متجانسة واستخداماتها
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
MX345926B (es) Nuevas composiciones, producción de las mismas y uso de las mismas para la producción de poliamidas coladas.
UA115373C2 (uk) Стабільний рідкий склад amg 416 (велкалсетиду)
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
TR201902741T4 (tr) Kişisel Temizlik Bileşimleri
EP2953470A4 (en) 2,6,7-SUBSTITUTED PURINS AS HDM2 INHIBITORS
MX2017012596A (es) Una composicion farmaceutica y el uso de la misma.
MX373845B (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio.
MX2016000219A (es) Compuestos neurotransmisores de dihidroxifenilo, composiciones y metodos.
MX2015016603A (es) Composiciones de corticosteroides.
EA201500927A1 (ru) Твердые липидные наночастицы (i)
EA201591725A1 (ru) Твердые липидные наночастицы (ii)
MX2016009696A (es) Formulaciones de antibióticos tópicas..
EA201690709A1 (ru) Применение одипарцила в лечении мукополисахаридоза
EA201890597A1 (ru) Содержащая цинеол водная композиция для назального применения